Format

Send to

Choose Destination
Leukemia. 2011 Feb;25(2):201-10. doi: 10.1038/leu.2010.215. Epub 2010 Sep 23.

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Author information

1
Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA. ejabbour@mdanderson.org

Erratum in

  • Leukemia. 2011 Feb;25(2):385.

Abstract

BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) constitute the cornerstone of treatment for chronic myeloid leukemia. Although these agents are normally safe and effective, they can cause side effects that lead to intolerance and necessitate switching to an alternative treatment. In this review, we describe side effects that occur during treatment with imatinib, nilotinib or dasatinib-the currently approved TKI treatments for chronic myeloid leukemia-including class effects and key differences in safety profiles. We also describe how common side effects can be effectively managed and offer a working definition of intolerance that may be useful to clinicians when they consider switching between TKIs.

PMID:
20861918
DOI:
10.1038/leu.2010.215
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center